Significant Modules and Biological Processes between Active Components of Salvia miltiorrhiza Depside Salt and Aspirin.

Yuan Li,Lianxin Wang,Yingying Zhang,Yan Chai,Hao Gu,Yanming Xie

doi:10.1155/2016/3439521

Abstract

The aim of this study is to examine and compare the similarities and differences between active components of S. miltiorrhiza depside salt and aspirin using perspective of pharmacological molecular networks. Active components of S. miltiorrhiza depside salt and aspirin's related genes were identified via the STITCH4.0 and GeneCards Database. A text search engine (Agilent Literature Search 2.71) and MCODE software were applied to construct network and divide modules, respectively. Finally, 32, 2, and 28 overlapping genes, modules, and pathways were identified between active components of S. miltiorrhiza depside salt and aspirin. A multidimensional framework of drug network showed that two networks reflected commonly in human aortic endothelial cells and atherosclerosis process. Aspirin plays a more important role in metabolism, such as the well-known AA metabolism pathway and other lipid or carbohydrate metabolism pathways. S. miltiorrhiza depside salt still plays a regulatory role in type II diabetes mellitus, insulin resistance, and adipocytokine signaling pathway. Therefore, this study suggests that aspirin combined with S. miltiorrhiza depside salt may be more efficient in treatment of CHD patients, especially those with diabetes mellitus or hyperlipidemia. Further clinical trials to confirm this hypothesis are still needed.

Highlights

Antithrombotic Therapy and Prevention of Thrombosis (Version 9) [1], announced by the American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines, proposed lasting low-dose aspirin therapy to be used as the primary prevention technique for patients above 50 years old or patients diagnosed with coronary heart disease (CHD)
After searching the STITCH (Homo sapiens, score > 0.400, medium confidence) and GeneCards Database, we found 55 genes related to active components of S. miltiorrhiza depside salt and 498 genes related to aspirin
There are 32 overlapping genes between aspirin and active components of S. miltiorrhiza depside salt, such as JUN, VCAM-1, TGFB1, TGFB1, IL8, IL1B, NOS2, NOS3, MAPK1, MAPK8, CASP3, MMP1, and MMP2 that have been associated with the cardiovascular diseases as biomarkers or therapeutic targets from the Comparative Toxicogenomics Database

Summary

Introduction

Antithrombotic Therapy and Prevention of Thrombosis (Version 9) [1], announced by the American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines, proposed lasting low-dose aspirin therapy to be used as the primary prevention technique for patients above 50 years old or patients diagnosed with coronary heart disease (CHD). Antithrombotic therapy plays a crucial role in prevention and treatment of CHD, in which aspirin undoubtedly is the most widely used conventional drug. A clinical noninferiority study showed that S. miltiorrhiza depside salt had definite therapeutic effect in patients with CHD angina pectoris, with no evidence of adverse drug reaction (ADR) [7]. Aspirin and S. miltiorrhiza depside salt are commonly used in CHD treatment, but the Evidence-Based Complementary and Alternative Medicine molecular relationships between the two drugs are still under study. A network pharmacology approach seems to be of interest as it would reveal the potential overlapping or unique modules that are affected by either treatment

Objectives

Methods

Findings

Discussion

Conclusion